Literature DB >> 7133817

Validation of an early language milestone scale in a high-risk population.

J Coplan, J R Gleason, R Ryan, M G Burke, M L Williams.   

Abstract

Detailed language evaluations were obtained by interviewing the parents of 191 healthy children aged 0 to 3 years, and by testing the children themselves. From these data, normative values were derived for 41 language milestones in the first 36 months of life. These values were used to construct the Early Language Milestone Scale (ELM Scale), a brief language assessment tool suitable for use by general pediatricians. Physician use of the ELM Scale in a population of 119 children considered at high risk for the presence of developmental disability yielded 97% sensitivity and 93% specificity for the ELM Scale as a detector of developmentally delayed children, when compared with more formal developmental measures as applied by a clinical psychologist or speech pathologist. Early language milestones are a sensitive indicator of developmental integrity; delayed achievement of early language milestones strongly suggests the presence of a significant underlying developmental disability. The ELM Scale may be adopted as a valid measure of developmental status among children considred at high risk for the presence of developmental disabilities.

Entities:  

Mesh:

Year:  1982        PMID: 7133817

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Evaluation of the child with deafness or delayed speech.

Authors:  J Coplan
Journal:  Indian J Pediatr       Date:  1988 May-Jun       Impact factor: 1.967

Review 2.  [Screening of language disorders in the preschool period].

Authors:  J Grégoire
Journal:  Can Fam Physician       Date:  1993-04       Impact factor: 3.275

3.  Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-phenotype correlation.

Authors:  P C Mainardi; C Perfumo; A Calì; G Coucourde; G Pastore; S Cavani; F Zara; J Overhauser; M Pierluigi; F D Bricarelli
Journal:  J Med Genet       Date:  2001-03       Impact factor: 6.318

4.  The social cognitive evaluation battery for children with autism: a new tool for the assessment of cognitive and social development in children with autism spectrum disorders.

Authors:  Eric Thiébaut; Jean-Louis Adrien; Romuald Blanc; Catherine Barthelemy
Journal:  Autism Res Treat       Date:  2010-10-24

5.  The impact of a specialist home-visiting intervention on the language outcomes of young mothers and their children: a pragmatic randomised controlled trial.

Authors:  Cerith S Waters; Rebecca Cannings-John; Susan Channon; Fiona Lugg-Widger; Mike Robling; Amy L Paine
Journal:  BMC Psychol       Date:  2022-09-23

Review 6.  Developmental Language Disorder: Early Predictors, Age for the Diagnosis, and Diagnostic Tools. A Scoping Review.

Authors:  Alessandra Sansavini; Maria Elena Favilla; Maria Teresa Guasti; Andrea Marini; Stefania Millepiedi; Maria Valeria Di Martino; Simona Vecchi; Nadia Battajon; Laura Bertolo; Olga Capirci; Barbara Carretti; Maria Paola Colatei; Cristina Frioni; Luigi Marotta; Sara Massa; Letizia Michelazzo; Chiara Pecini; Silvia Piazzalunga; Manuela Pieretti; Pasquale Rinaldi; Renata Salvadorini; Cristiano Termine; Mariagrazia Zuccarini; Simonetta D'Amico; Anna Giulia De Cagno; Maria Chiara Levorato; Tiziana Rossetto; Maria Luisa Lorusso
Journal:  Brain Sci       Date:  2021-05-17

7.  The effectiveness and cost-effectiveness of the Family Nurse Partnership home visiting programme for first time teenage mothers in England: a protocol for the Building Blocks randomised controlled trial.

Authors:  Eleri Owen-Jones; Marie-Jet Bekkers; Chris C Butler; Rebecca Cannings-John; Sue Channon; Kerenza Hood; John W Gregory; Alison Kemp; Joyce Kenkre; Belen Corbacho Martin; Alan Montgomery; Gwenllian Moody; Kate E Pickett; Gerry Richardson; Zoë Roberts; Sarah Ronaldson; Julia Sanders; Eugena Stamuli; David Torgerson; Michael Robling
Journal:  BMC Pediatr       Date:  2013-08-06       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.